Algo version: 0.98b
Medicamen Biotech Limited is listed at the NSE Exchange
Medicamen Biotech Limited [MEDICAMEQ.NS]
NSE Sector: Healthcare Industry:Drug Manufacturers—Specialty & Generic

Is Medicamen Biotech Limited stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Medicamen Biotech Limited pays dividends. Last time was Saturday 26th of October 2024 where the investors holding the stock on Wednesday 18th of September 2024 were paid INR1 per share. Over the last 3 times between 2022 and 2024, Medicamen Biotech Limited has paid INR3 with an average of INR1 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Medicamen Biotech Limited 10 years ago, but if you had invested on Wednesday 27th of October 2021 when the price was INR552.00, you would have made a loss of INR-134.75 per share or -24.41%

Yes, the average daily trading liquidity for Medicamen Biotech Limited is INR25 823 thousand. You should therefore be able to get in and out of your positions relatively fast.

Medicamen Biotech Limited has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.45, the company's ability to pay off the debt is normal. Medicamen Biotech Limited has a good net profit margin of 5.47% and should have high tolerances against inflation.

We have calculated the inflation risk for Medicamen Biotech Limited to be low [0.4 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.